BACKGROUND: Despite advances in therapy, the majority of adult patients diagnosed with acute myeloid leukemia (AML) develop disease recurrence and die of their disease. Early intensification of treatment for AML using timed sequential therapy (TST) has been proposed as a means of improving the survival outcome in children. The Children's Cancer Group demonstrated that children with AML who were randomized to receive 2 courses of daunorubicin, cytarabine, thioguanine, etoposide, and dexamethasone (the DCTER regimen) given 10 days apart had an improved event-free survival (EFS) and disease-free survival (DFS) (42% ± 7% and 55% ± 9%, respectively, at 2 years). Reports have suggested an improved outcome in adult patients with AML usingTST (at the cost of increased toxicity). The current study was conducted to evaluate the feasibility and effectiveness of the intensively timed DCTER regimen for non-core-binding factor AML in adult patients aged <50 years. METHODS:Between February 2004 and August 2005, 61 patients received thistimed sequential induction regimen. Their outcomes were compared with matched historical patients treated with the combination of idarubicin and cytarabine (IA). RESULTS: The median follow-up for surviving patients was 67 months (range, 35-85 months). The timed sequential DCTER regimen had a lower complete remission (CR) rate when compared with the IA combination,, (71% vs 80%, respectively), but this appeared to be counterbalanced by a higher long-term leukemia-free survival rate using the intensified regimen (48% vs 30%, respectively) in patients who achieved a CR (P = .06). CONCLUSIONS: The intensively timed regimen of DCTER was found to induce durable remissions in adult patients with AML, including those patients with high-risk disease. The identification of patients who would potentially benefit from such an intensive regimen may justify the higher early risk of early treatment failure that was found to accompany the intensified DCTER regimen in selected patients.
RCT Entities:
BACKGROUND: Despite advances in therapy, the majority of adult patients diagnosed with acute myeloid leukemia (AML) develop disease recurrence and die of their disease. Early intensification of treatment for AML using timed sequential therapy (TST) has been proposed as a means of improving the survival outcome in children. The Children's Cancer Group demonstrated that children with AML who were randomized to receive 2 courses of daunorubicin, cytarabine, thioguanine, etoposide, and dexamethasone (the DCTER regimen) given 10 days apart had an improved event-free survival (EFS) and disease-free survival (DFS) (42% ± 7% and 55% ± 9%, respectively, at 2 years). Reports have suggested an improved outcome in adult patients with AML using TST (at the cost of increased toxicity). The current study was conducted to evaluate the feasibility and effectiveness of the intensively timed DCTER regimen for non-core-binding factorAML in adult patients aged <50 years. METHODS: Between February 2004 and August 2005, 61 patients received this timed sequential induction regimen. Their outcomes were compared with matched historical patients treated with the combination of idarubicin and cytarabine (IA). RESULTS: The median follow-up for surviving patients was 67 months (range, 35-85 months). The timed sequential DCTER regimen had a lower complete remission (CR) rate when compared with the IA combination,, (71% vs 80%, respectively), but this appeared to be counterbalanced by a higher long-term leukemia-free survival rate using the intensified regimen (48% vs 30%, respectively) in patients who achieved a CR (P = .06). CONCLUSIONS: The intensively timed regimen of DCTER was found to induce durable remissions in adult patients with AML, including those patients with high-risk disease. The identification of patients who would potentially benefit from such an intensive regimen may justify the higher early risk of early treatment failure that was found to accompany the intensified DCTER regimen in selected patients.
Authors: W G Woods; N Kobrinsky; J D Buckley; J W Lee; J Sanders; S Neudorf; S Gold; D R Barnard; J DeSwarte; K Dusenbery; D Kalousek; D C Arthur; B J Lange Journal: Blood Date: 1996-06-15 Impact factor: 22.113
Authors: Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544
Authors: Richard M Stone; Daniel J DeAngelo; Virginia Klimek; Ilene Galinsky; Eli Estey; Stephen D Nimer; Wilson Grandin; David Lebwohl; Yanfeng Wang; Pamela Cohen; Edward A Fox; Donna Neuberg; Jennifer Clark; D Gary Gilliland; James D Griffin Journal: Blood Date: 2004-09-02 Impact factor: 22.113
Authors: R L Capizzi; R Davis; B Powell; J Cuttner; R R Ellison; M R Cooper; R Dillman; W B Major; E Dupre; O R McIntyre Journal: J Clin Oncol Date: 1988-03 Impact factor: 44.544
Authors: Jan Braess; Karsten Spiekermann; Peter Staib; Andreas Grüneisen; Bernhard Wörmann; Wolf-Dieter Ludwig; Hubert Serve; Albrecht Reichle; Rudolf Peceny; Daniel Oruzio; Christoph Schmid; Xaver Schiel; Marcus Hentrich; Christina Sauerland; Michael Unterhalt; Michael Fiegl; Wolfgang Kern; Christian Buske; Stefan Bohlander; Achim Heinecke; Herrad Baurmann; Dietrich W Beelen; Wolfgang E Berdel; Thomas Büchner; Wolfgang Hiddemann Journal: Blood Date: 2009-01-08 Impact factor: 22.113
Authors: D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone Journal: Blood Date: 1998-10-01 Impact factor: 22.113
Authors: Joshua F Zeidner; Matthew C Foster; Amanda L Blackford; Mark R Litzow; Lawrence E Morris; Stephen A Strickland; Jeffrey E Lancet; Prithviraj Bose; M Yair Levy; Raoul Tibes; Ivana Gojo; Christopher D Gocke; Gary L Rosner; Richard F Little; John J Wright; L Austin Doyle; B Douglas Smith; Judith E Karp Journal: Haematologica Date: 2015-05-28 Impact factor: 9.941
Authors: Kelly J Norsworthy; Amy E DeZern; Hua-Ling Tsai; Wesley A Hand; Ravi Varadhan; Steven D Gore; Ivana Gojo; Keith Pratz; Hetty E Carraway; Margaret Showel; Michael A McDevitt; Douglas Gladstone; Gabriel Ghiaur; Gabrielle Prince; Amy H Seung; Dina Benani; Mark J Levis; Judith E Karp; B Douglas Smith Journal: Leuk Res Date: 2017-08-30 Impact factor: 3.156
Authors: William G Woods; Anna R K Franklin; Todd A Alonzo; Robert B Gerbing; Kathleen A Donohue; Megan Othus; John Horan; Frederick R Appelbaum; Elihu H Estey; Clara D Bloomfield; Richard A Larson Journal: Cancer Date: 2013-09-19 Impact factor: 6.860
Authors: Isabelle Laverdière; Meaghan Boileau; Andrea L Neumann; Héloïse Frison; Amanda Mitchell; Stanley W K Ng; Jean C Y Wang; Mark D Minden; Kolja Eppert Journal: Blood Cancer J Date: 2018-06-06 Impact factor: 11.037